Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 289 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: tamoxifen citrate Clear all
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

NCT06154590
View directory record Official record
Conditions
Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions
Method(s)1 Attribution, Method(s)2 Attribution,
Drug
Lead sponsor
DR. DIANE CHISESI NFS. MD. PHD.
Other
Eligibility
44 Years to 59 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2Phase 3 Interventional

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

NCT00065767
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Raloxifene
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 1, 2026, 7:48 PM EDT
Recruiting No phase listed Observational

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

NCT05051722
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions
Vaginal Fluid Collection, Blood Collection
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

NCT02788201
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)

NCT00028353
View directory record Official record
Conditions
Prostatic Intraepithelial Neoplasia
Interventions
GTX-006 (Acapodene)
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Aventura, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 1, 2026, 7:48 PM EDT
Terminated Phase 2 Interventional

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

NCT00206492
View directory record Official record
Conditions
Breast Cancer
Interventions
Iressa, Tamoxifen
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

NCT02291913
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 1, 2026, 7:48 PM EDT
Recruiting Early Phase 1 Interventional

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

NCT04174352
View directory record Official record
Conditions
ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions
Tamoxifen, FES PET/CT
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 1, 2026, 7:48 PM EDT
Terminated No phase listed Observational

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00899197
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate, gene expression analysis, protein expression analysis, immunoenzyme technique, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

NCT00332553
View directory record Official record
Conditions
Vasomotor Symptoms, Endometrial Safety
Interventions
Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer

NCT00003050
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 4 Interventional

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

NCT00532246
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
La Jolla, California • Menlo Park, California • Oakland, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

NCT01124695
View directory record Official record
Conditions
Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 203 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 1, 2026, 7:48 PM EDT
Recruiting No phase listed Observational

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

NCT01788839
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Interventions
surveys, Blood draw, Transvaginal ultrasounds
Behavioral · Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block (SGB) For Women for Breast Cancer

NCT02513329
View directory record Official record
Conditions
Hot Flushes, Hot Flashes
Interventions
Bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 1, 2026, 7:48 PM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 1, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Goserelin, Tamoxifen 20 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
35
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 1, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

NCT06184750
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Mammography, Questionnaire Administration, Tamoxifen
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Tucson, Arizona • Chicago, Illinois • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 1, 2026, 7:48 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound

NCT01579227
View directory record Official record
Conditions
Scar
Interventions
Topical Tocotrienol (TCT), Oral Tocotrienol Capsules (TCT), Tamoxifen Cream, Placebo cream, placebo capsule
Device · Dietary Supplement
Lead sponsor
Chandan K Sen
Other
Eligibility
18 Years to 50 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

NCT02824224
View directory record Official record
Conditions
Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions
Tamoxifen, Placebo (for Tamoxifen)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 1, 2026, 7:48 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

NCT04272801
View directory record Official record
Conditions
Breast Cancer Female
Interventions
tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes
Drug · Behavioral
Lead sponsor
Shayna Showalter, MD
Other
Eligibility
65 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515
View directory record Official record
Conditions
Solid Tumor
Interventions
MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 1, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

NCT02384239
View directory record Official record
Conditions
Metastatic Breast Cancer, Hormone Receptor Positive
Interventions
Palbociclib, Tamoxifen, Fulvestrant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 1, 2026, 7:48 PM EDT